UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 145

Sortiert nach

Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis

Journal of hematology and oncology, 2022-06, Vol.15 (1), p.72-72, Article 72

2022

Link zum Volltext

Verfügbarkeit prüfen

CXCL12, a potential modulator of tumor immune microenvironment (TIME) of bladder cancer: From a comprehensive analysis of TCGA database

Frontiers in oncology, 2022-11, Vol.12, p.1031706-1031706

2022

Link zum Volltext

Verfügbarkeit prüfen

Real-world data of triplet combination of pyrotinib, trastuzumab, and chemotherapy in HER2-positive metastatic breast cancer: a multicenter, retrospective study

Therapeutic advances in medical oncology, 2023-01, Vol.15, p.17588359231217972-17588359231217972

2023

Link zum Volltext

Verfügbarkeit prüfen

Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis

Frontiers in endocrinology (Lausanne), 2023-12, Vol.14, p.1325540-1325540

2023

Link zum Volltext

Verfügbarkeit prüfen

Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer

Frontiers in immunology, 2022-11, Vol.13, p.1056932-1056932

2022

Link zum Volltext

Verfügbarkeit prüfen

Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer

Frontiers in endocrinology (Lausanne), 2023-10, Vol.14, p.1270453-1270453

2023

Link zum Volltext

Verfügbarkeit prüfen

ER status conversion and subsequent treatment: an assessment of negative ER expression detected by 18F-FES PET in metastatic breast cancer patients with ER-positive primary tumors

Therapeutic advances in medical oncology, 2023-01, Vol.15, p.17588359231216093-17588359231216093

2023

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2- Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study

Scientific reports, 2018-09, Vol.8 (1), p.14458-7, Article 14458

2018

Link zum Volltext

Verfügbarkeit prüfen

Pretreatment 18F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer

Cancer imaging, 2023-09, Vol.23 (1), p.1-90, Article 90

2023

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by 18F-FES PET

Cancers, 2022-07, Vol.14 (14), p.3531

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases

BMC cancer, 2021-11, Vol.21 (1), p.1174-1174

2021

Link zum Volltext

Verfügbarkeit prüfen

Chromatin Remodelling Molecule ARID1A Determines Metastatic Heterogeneity in Triple-Negative Breast Cancer by Competitively Binding to YAP

Cancers, 2023-04, Vol.15 (9), p.2447

2023

Link zum Volltext

Verfügbarkeit prüfen

Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study

Frontiers in oncology, 2021-08, Vol.11, p.699333-699333

2021

Link zum Volltext

Verfügbarkeit prüfen

Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study

Therapeutic advances in medical oncology, 2021, Vol.13, p.175883592110302-17588359211030210

2021

Link zum Volltext

Verfügbarkeit prüfen

Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score–matched analysis of real-world data

Therapeutic advances in drug safety, 2022-01, Vol.13, p.20420986221146411-20420986221146411

2022

Link zum Volltext

Verfügbarkeit prüfen

Heterogeneity derived from 18F‐FDG PET/CT predicts immunotherapy outcome for metastatic triple‐negative breast cancer patients

Cancer medicine (Malden, MA), 2022-05, Vol.11 (9), p.1948-1955

2022

Link zum Volltext

Verfügbarkeit prüfen

Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer

Scientific reports, 2019-03, Vol.9 (1), p.3563-3563, Article 3563

2019

Link zum Volltext

Verfügbarkeit prüfen

Cuproptosis-related risk score predicts prognosis and characterizes the tumor microenvironment in colon adenocarcinoma

Frontiers in oncology, 2023-06, Vol.13, p.1152681-1152681

2023

Link zum Volltext

Verfügbarkeit prüfen

Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study

Scientific reports, 2019-02, Vol.9 (1), p.1710, Article 1710

2019

Link zum Volltext

Verfügbarkeit prüfen

Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of 18F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer

Cancers, 2022-08, Vol.14 (16), p.3973

2022

Link zum Volltext

Verfügbarkeit prüfen

Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study

Cancer medicine (Malden, MA), 2020-05, Vol.9 (9), p.2981-2988

2020

Link zum Volltext

Verfügbarkeit prüfen

Negative estrogen receptor expression assessed by 18F-FES PET in metastatic breast cancer with ER-positive primary tumor

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.1034-1034

2023

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapy shows better efficacy than endocrine therapy in patients with metastatic breast cancer with heterogeneous estrogen receptor expression

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.1050-1050

2022

Link zum Volltext

Verfügbarkeit prüfen

Extracellular mechanical forces and ferroptosis in triple negative breast cancer (TNBC): Targeting of aurora kinase A (AURKA)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e13086-e13086

2023

Link zum Volltext

Verfügbarkeit prüfen

PO109 REAL-WORLD DATA OF TRIPLET COMBINATION OF PYROTINIB, TRASTUZUMAB, AND CHEMOTHERAPY IN HER2-POSITIVE METASTATIC BREAST CANCER: A MULTICENTER, RETROSPECTIVE STUDY

Breast (Edinburgh), 2023-10, Vol.71, p.S52

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 145

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(138)
Mit Volltextzugriff
(142)

Publikationsform

Sprache

Englisch
(143)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Science & Technology
(92)
Life Sciences & Biomedicine
(49)
Physical Sciences
(30)
Breast Cancer
(26)
Chemistry
(24)
Technology
(22)
Metastasis
(20)
Oncology
(20)
Chemotherapy
(15)
Materials Science
(15)
Metastatic Breast Cancer
(14)
Patients
(14)
Chemistry, Physical
(13)
Metastases
(13)
Humans
(12)
Science & Technology - Other Topics
(12)
Cancer Therapies
(11)
Materials Science, Multidisciplinary
(11)
Prognosis
(11)
Tumors
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis

CXCL12, a potential modulator of tumor immune microenvironment (TIME) of bladder cancer: From a comprehensive analysis of TCGA database

Real-world data of triplet combination of pyrotinib, trastuzumab, and chemotherapy in HER2-positive metastatic breast cancer: a multicenter, retrospective study

Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis

Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer

Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer

ER status conversion and subsequent treatment: an assessment of negative ER expression detected by 18F-FES PET in metastatic breast cancer patients with ER-positive primary tumors

Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2- Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study

Pretreatment 18F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer

Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by 18F-FES PET

Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases

Chromatin Remodelling Molecule ARID1A Determines Metastatic Heterogeneity in Triple-Negative Breast Cancer by Competitively Binding to YAP

Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study

Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study

Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score–matched analysis of real-world data

Heterogeneity derived from 18F‐FDG PET/CT predicts immunotherapy outcome for metastatic triple‐negative breast cancer patients

Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer

Cuproptosis-related risk score predicts prognosis and characterizes the tumor microenvironment in colon adenocarcinoma

Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study

Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of 18F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer

Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study

Negative estrogen receptor expression assessed by 18F-FES PET in metastatic breast cancer with ER-positive primary tumor

Chemotherapy shows better efficacy than endocrine therapy in patients with metastatic breast cancer with heterogeneous estrogen receptor expression

Extracellular mechanical forces and ferroptosis in triple negative breast cancer (TNBC): Targeting of aurora kinase A (AURKA)

PO109 REAL-WORLD DATA OF TRIPLET COMBINATION OF PYROTINIB, TRASTUZUMAB, AND CHEMOTHERAPY IN HER2-POSITIVE METASTATIC BREAST CANCER: A MULTICENTER, RETROSPECTIVE STUDY

Suchergebnisse filtern